Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study finds poorer outcomes after ICU discharge in patients with alcohol-associated cirrhosis

by Medical Finance
in Coronavirus
Study finds poorer outcomes after ICU discharge in patients with alcohol-associated cirrhosis
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Patients with alcohol-associated cirrhosis have poorer outcomes after ICU discharge, compared to patients with cirrhosis linked to other causes, according to new Mayo Clinic research.

Cirrhosis is a scarring of the liver that damages function and can be life-threatening. Almost half of all cirrhosis deaths are attributed to chronic alcohol use disorder, with the rest caused by hepatitis and other forms of liver disease. Over 7 deaths per 100,000 worldwide are linked to alcohol-associated cirrhosis.

According to the new study published in Mayo Clinic Proceedings, patients with alcohol-associated cirrhosis had significantly higher post-ICU, in-hospital death rate – 10% versus 6.5% – as well as higher mortality at the 30-day benchmark after ICU discharge – 18.7% versus 11.2% – than patients with cirrhosis attributed to other causes.

Clinical outcomes of patients with alcohol-associated cirrhosis have been reported in previous studies, with conflicting results. Our study demonstrates that although there is no significant difference in ICU mortality in patients with ALC, as compared to other causes, there was a significant difference in mortality for patients who survive their ICU stay up to 30 days later.”


Douglas Simonetto, MD, Study Senior Author and Gastroenterologist, Mayo Clinic

Previous studies have attributed a higher prevalence of infection as the reason for increased mortality in patients with alcohol-associated cirrhosis, compared to patients without alcohol-associated cirrhosis. “In our study, the infection rates were similar among the two groups,” Dr. Simonetto says. “But when infection was present, it was associated with higher mortality in ALC.”

The retrospective study analyzed case files for 1,174 patients who were admitted to the ICU at Mayo Clinic between January 2006 and December 2015. Patients were about evenly split between those with alcohol-associated cirrhosis and those with cirrhosis linked to other causes. Researchers focused on survival rates within the ICU, after the ICU and in the hospital, and at 30 days after being discharged from the ICU.

The mean age of patients in the study was 59, and 60% were male. Among alcohol-associated cirrhosis patients, 69.2% had cirrhosis caused by alcohol use alone and 30.8% had cirrhosis due to alcohol plus an additional cause, such as viral hepatitis C. About half of the patients with alcohol-associated cirrhosis continued to drink until the ICU admission, while 36.7% quit six months or longer before admission.

“Surprisingly, there was no significant difference in survival for patients who abstained from alcohol six months or more before ICU admission and those who did not,” says Chansong Choi, M.D., a Mayo Clinic internal medicine resident and the study’s lead author. “This may reflect too short a period of abstinence, as other studies have suggested that at least one to 1½ years of abstinence might be needed to make a significant difference in survival outcomes in patients with ALC.”

Early diagnosis of sepsis, a potentially life-threatening condition that occurs when the body’s response to infection damages its own tissues, is critical in patients with cirrhosis who are admitted to the ICU. Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) has been proposed as a simple tool for early detection of sepsis, but the Mayo Clinic study finds qSOFA has limited clinical usefulness and applicability for patients with cirrhosis.

“Our study finds that qSOFA is a poor prognosticator of sepsis and in-hospital mortality among patients with cirrhosis,” says Dr. Choi. “We need better bedside tools to predict infection and sepsis in these patient groups so we can implement the appropriate therapeutic measures.”

Source:

Journal reference:

Choi, C., et al. (2021) Relationship Between Etiology of Cirrhosis and Survival Among Patients Hospitalized in Intensive Care Units. Mayo Clinic Proceedings. doi.org/10.1016/j.mayocp.2021.08.025.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Accuracy of Rapid Antigen Testing across SARS-CoV-2 Variants. Image Credit: Ian Gessey/Shutterstock

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated clinical accuracy and analytical detection capabilities of the...

Investigation: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. Image Credit: Marina Demidiuk / Shutterstock

Is COVID-19 vaccination during pregnancy safe?

by Medical Finance
May 19, 2022
0

A new retrospective cohort study conducted across a large population of pregnant women in Ontario, Canada, has confirmed that the...

Study: Specific Intracellular Signature of SARS-CoV-2 Infection Using Confocal Raman Microscopy. Image Credit: joshimerbin/Shutterstock

Investigating SARS-CoV-2 detection using Raman microscopy

by Medical Finance
May 19, 2022
0

A recent study posted to the Research Square* preprint server, and currently under consideration at a Nature Portfolio Journal, investigated the...

Study: Cellulosic copper nanoparticles and a hydrogen peroxide-based disinfectant protect Vero E6 cells against infection by viral pseudotyped particles expressing SARS-CoV-2, SARS-CoV or MERS-CoV Spike protein. Image Credit: Matthias Friel/Shutterstock

Study indicates combining a hydrogen peroxide-based disinfectant with cellulosic copper nanoparticles lowers human coronaviruses’ infectivity

by Medical Finance
May 19, 2022
0

A recent study posted to the bioRxiv* preprint server indicated that combining a hydrogen peroxide (H2O2)-based disinfectant and cellulosic copper (Cu)...

Perspective: Superantigens and SARS-CoV-2. ​​​​​​​Image Credit: Corona Borealis Studio / Shutterstock

Is SARS-CoV-2 a Superantigen?

by Medical Finance
May 20, 2022
0

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), scientists have...

Study: Understanding T-cell responses to COVID-19 is essential for informing public health strategies. Image Credit: ESB Professional/Shutterstock

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

by Medical Finance
May 19, 2022
0

A recent viewpoint published in the journal Science Immunology illustrated that evaluating T cell responses to coronavirus disease 2019 (COVID-19) is essential...

Next Post
Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Researchers show the feasibility of a comprehensive sequencing approach in pediatric and young adult cancers

NPS

Tackling the Global Issue of New Psychoactive Substances

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • 174318220 620x480
    Black patients with cancer experience worse outcomes after COVID-19 diagnosis
  • Study: Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody. Image Credit: Huen Structure Bio / Shutterstock
    Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply